Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group.
Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagné SE, Jansen H, Seidell JC, Kromhout D, Jukema JW, Bruschke AV, Boerwinkle E, Hayden MR. Kastelein JJ, et al. Among authors: bruschke av. Clin Genet. 1998 Jan;53(1):27-33. doi: 10.1034/j.1399-0004.1998.531530106.x. Clin Genet. 1998. PMID: 9550358
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Among authors: bruschke av. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.
Groenemeijer BE, Hallman MD, Reymer PW, Gagné E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Groenemeijer BE, et al. Among authors: bruschke av. Circulation. 1997 Jun 17;95(12):2628-35. doi: 10.1161/01.cir.95.12.2628. Circulation. 1997. PMID: 9193431 Clinical Trial.
Thermolabile methylenetetrahydrofolate reductase in coronary artery disease.
Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, Jukema JW, van den Heuvel LP, Trijbels FJ, Boerma GJ, Verheugt FW, Willems F, Blom HJ. Kluijtmans LA, et al. Among authors: bruschke av. Circulation. 1997 Oct 21;96(8):2573-7. doi: 10.1161/01.cir.96.8.2573. Circulation. 1997. PMID: 9355896
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. Kuivenhoven JA, et al. Among authors: bruschke av. N Engl J Med. 1998 Jan 8;338(2):86-93. doi: 10.1056/NEJM199801083380203. N Engl J Med. 1998. PMID: 9420339 Free article. Clinical Trial.
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group.
de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. de Maat MP, et al. Among authors: bruschke av. Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):265-71. doi: 10.1161/01.atv.18.2.265. Arterioscler Thromb Vasc Biol. 1998. PMID: 9484992 Review.
179 results